Functional connectivity associated with improvement in emotion management after cognitive enhancement therapy in early-course schizophrenia.

BACKGROUND: The ability to manage emotions is an important social-cognitive domain impaired in schizophrenia and linked to functional outcome. The goal of our study was to examine the impact of cognitive enhancement therapy (CET) on the ability to manage emotions and brain functional connectivity in early-course schizophrenia. METHODS: Participants were randomly assigned to CET (n = 55) or an enriched supportive therapy (EST) control group (n = 45). The resting-state functional magnetic resonance imaging scans and measures of emotion management performances were collected at baseline, 9, and 18 months follow-up. The final sample consisted of 37 CET and 25 EST participants, including 19 CET and 12 EST participants with imaging data. Linear mixed-effects models investigated the impact of treatment on emotion management and functional connectivity from the amygdala to ventrolateral and dorsolateral prefrontal cortex (dlPFC). RESULTS: The CET group showed significant improvement over time in emotion management compared to EST. Neither functional connectivity changes nor main group differences were observed following treatment. However, a significant between-group interaction showed that improved emotion management ability was associated with increased functional connectivity between the left amygdala and the left dlPFC in the CET group exclusively. CONCLUSION: Our results replicate the previous work demonstrating that CET is effective at improving some aspects of social cognition in schizophrenia. We found evidence that improvement in emotion management may be associated with a change in amygdala-dlPFC connectivity. This fronto-limbic circuit may provide a mechanistic link between the biology of emotion management processes that can be enhanced in individuals with schizophrenia.

Individual variation in brain network topology is linked to emotional intelligence.

BACKGROUND: Social cognitive ability is a significant determinant of functional outcome, and deficits in social cognition are a disabling symptom of psychotic disorders. The neurobiological underpinnings of social cognition are not well understood, hampering our ability to ameliorate these deficits. OBJECTIVE: Using 'resting state' functional magnetic resonance imaging (rsfMRI) and a trans-diagnostic, data-driven analytic strategy, we sought to identify the brain network basis of emotional intelligence, a key domain of social cognition. METHODS: The study included 60 participants with a diagnosis of schizophrenia or schizoaffective disorder and 45 healthy controls. All participants underwent a rsfMRI scan. Emotional Intelligence was measured using the Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT). A connectome-wide analysis examined how each individual brain voxel's connectivity correlated with emotional intelligence using multivariate distance matrix regression (MDMR). RESULTS: We identified a region in the left superior parietal lobule (SPL) where individual network topology is linked to emotional intelligence. Specifically, in high scoring individuals, this region is a node of the Default Mode Network and in low scoring individuals, it is a node of the Dorsal Attention Network. This relationship was observed in both schizophrenia and healthy comparison participants. CONCLUSION: Prior studies have demonstrated individual variance in the topology of canonical resting state networks but the cognitive or behavioral relevance of these differences has largely been undetermined. We observe that the left SPL, a region of high individual variance at the cytoarchitectonic level, also demonstrates individual variance in its association with large scale resting-state networks and that network topology is linked to emotional intelligence.

Structure and catalysis by carbonic anhydrase II: role of active-site tryptophan 5.

The tryptophan residue Trp5, highly conserved in the α class of carbonic anhydrases including human carbonic anhydrase II (HCA II), is positioned at the entrance of the active site cavity and forms a π-stacking interaction with the imidazole ring of the proton shuttle His64 in its outward orientation. We have observed that replacement of Trp5 in HCA II caused significant structural changes, as determined by X-ray diffraction, in the conformation of 11 residues at the N-terminus and in the orientation of the proton shuttle residue His64. Most significantly, two variants W5H and W5E HCA II had His64 predominantly outward in orientation, while W5F and wild type showed the superposition of both outward and inward orientations in crystal structures. Although Trp5 influences the orientation of the proton shuttle His64, this orientation had no significant effect on the rate constant for proton transfer near 1µs(-1), determined by exchange of (18)O between CO(2) and water measured by mass spectrometry. The apparent values of the pK(a) of the zinc-bound water and the proton shuttle residue suggest that different active-site conformations influence the two stages of catalysis, the proton transfer stage and the interconversion of CO(2) and bicarbonate.

Para-derivatized pybox ligands as sensitizers in highly luminescent Ln(III) complexes.

New complexes of pyridine-bis(oxazoline) derivatized with -H, -OMe, and -Br at the para position of the pyridine ring with Eu(III) and Tb(III) have been isolated. These are highly luminescent in the solid state, regardless of the ligand-to-metal ratio. Several of the metal complexes were isolated and characterized by single crystal X-ray diffraction, showing the rich diversity of structures that can be obtained with this family of ligands. [Eu(PyboxOMe)(3)](NO(3))(3)·3CH(2)Cl(2), 1, crystallizes in the monoclinic space group P2(1)/n and has the cell parameters a = 14.3699(10) Å, b = 13.4059(9) Å, c = 25.8766(18) Å, ß = 95.367(1)°, and V = 4963.1(6) Å(3). The isostructural [Tb(PyboxOMe)(3)](NO(3))(3)·3CH(2)Cl(2), 2, crystallizes with the parameters a = 14.4845(16) Å, b = 13.2998(15) Å, c = 25.890(3) Å, ß = 94.918(2)°, and V = 4969.1(10) Å(3). 3, a 1:1 complex with the formula [Eu(PyboxBr)(NO(3))(3)(H(2)O)], crystallizes in the monoclinic P2(1)/c space group with a = 11.649(2) Å, b = 8.3914(17) Å, c = 20.320(4) Å, ß = 100.25(3)°, and V = 1954.5(7) Å(3). 4, a product of the reaction of PyboxBr with Tb(NO(3))(3), is [Tb(PyboxBr)(2)(η(2)-NO(3))(η(1)-NO(3)](2)[Tb(NO(3))(5)]·5H(2)O. It crystallizes in the monoclinic space group P2(1) with a = 15.612(3) Å, b = 14.330(3) Å, c = 16.271(3) Å, ß = 92.58(3)°, and V = 3636.5(13) Å(3). [Tb(Pybox)(3)](CF(3)SO(3))(3)·3CH(2)CN, 5, crystallizes in the triclinic space group P1̅ with a = 12.3478(2) Å, b = 15.0017(2) Å, c = 16.1476(4) Å, α = 100.252(1)°, ß = 100.943(1)°, γ = 113.049(1)°, and V = 2594.80(8) Å(3). Finally, compound 6, [Tb(Pybox)(2)(NO(3))(H(2)O)](NO(3))(2)·CH(3)OH, crystallizes in the triclinic P1̅ space group with a = 9.7791(2) Å, b = 10.1722(2) Å, c = 15.3368(3) Å, α = 83.753(1)°, ß = 78.307(1)°, γ = 85.630(1)°, and V = 1482.33(5) Å(3). In solution, the existence of 3:1, 2:1, and 1:1 species can be observed through absorption and luminescence speciation measurements as well as NMR spectroscopy. The stability constants in acetonitrile, as an average obtained from absorption and emission titrations, are log ß(11) = 5.4, log ß(12) = 8.8, and log ß(13) = 12.8 with Eu(III) and log ß(11) = 4.5, log ß(12) = 8.4, and log ß(13) = 11.7 for the Tb(III) species with PyboxOMe. Pybox displayed stability constants log ß(11) = 3.6, log ß(12) = 9.1, and log ß(13) = 12.0 with Eu(III) and log ß(11) = 3.7, log ß(12) = 9.3, and log ß(13) = 12.2 for the Tb(III) species. Finally, PyboxBr yielded log ß(11) = 7.1, log ß(12) = 12.2, and log ß(13) = 15.5 for the Eu(III) species and log ß(11) = 6.2, log ß(12) = 11.0, and log ß(13) = 15.4 with Tb(III). Photophysical characterization was performed in all cases on solutions with 3:1 ligand-to-metal ion stoichiometry and allowed determination of quantum yields and lifetimes of emission for PyboxOMe of 23.5 ± 1.6% and 1.54 ± 0.04 ms for Eu(III) and 21.4 ± 3.6% and 1.88 ± 0.04 ms for Tb(III). For Pybox these values were 25.6 ± 1.1% and 1.49 ± 0.04 ms for Eu(III) and 23.2 ± 2.1% and 0.44 ± 0.01 ms for Tb(III) and for PyboxBr they were 35.8 ± 1.6% and 1.46 ± 0.03 ms for Eu(III) and 23.3 ± 1.3% and a double lifetime of 0.79 ± 0.05/0.07 ± 0.01 ms for Tb(III). A linear relationship between the triplet level energies and the Hammett σ constants was found. Lifetime measurements in methanol as well as the NMR data in both methanol and acetonitrile indicate that all complexes are stable in the 3:1 stoichiometry in solution and that there is no solvent coordination to the metal ion.

Association of Choroid Plexus Enlargement With Cognitive, Inflammatory, and Structural Phenotypes Across the Psychosis Spectrum.

OBJECTIVE: The choroid plexus is an important physiological barrier and produces CSF and neurotrophic, angiogenic, and inflammatory factors involved in brain development. Choroid plexus abnormalities have been implicated in both schizophrenia and bipolar disorder. A previous choroid plexus transcriptomic analysis of schizophrenia identified an upregulation of immune and inflammatory genes that correlated with peripheral inflammatory markers. The purpose of this study was to examine choroid plexus volume in probands across the psychosis spectrum and in their first-degree and axis II cluster A relatives, as well as choroid plexus familiality and choroid plexus covariance with clinical, cognitive, brain, and peripheral marker measures. METHODS: Choroid plexus volume was quantified (using FreeSurfer) in psychosis probands, their first-degree and axis II cluster A relatives, and healthy control subjects, organized by DSM-IV-TR diagnosis. Analyte, structural connectivity, and genotype data were collected from a subset of study subjects. RESULTS: Choroid plexus volume was significantly larger in probands compared with first-degree relatives or healthy control subjects; first-degree relatives had intermediate enlargement compared with healthy control subjects; and total choroid plexus volume was significantly heritable. Larger volume was associated with worse cognition, smaller total gray matter and amygdala volume, larger lateral ventricle volume, and lower structural connectivity in probands. Associations between larger volume and higher levels of interleukin 6 in probands was also observed. CONCLUSIONS: These findings suggest the involvement of the choroid plexus across the psychosis spectrum with a potential pathophysiological mechanism involving the neuroimmune axis, which functions in maintaining brain homeostasis and interacting with the peripheral immune and inflammatory system. The choroid plexus may be an important target in future research.

VEGFA GENE variation influences hallucinations and frontotemporal morphology in psychotic disorders: a B-SNIP study.

Vascular endothelial growth factor A (VEGFA) dysfunction may contribute to a number of pathological processes that characterize psychotic disorders. However, the influence of VEGFA gene variants on clinical and neuroimaging phenotypes in psychotic disorders has yet to be shown. In the present study, we examined whether different VEGFA gene variants influence psychosis risk, symptom severity, cognition, and brain volume. The study group included 480 probands (Bipolar I disorder with psychosis, n = 205; Schizoaffective disorder, n = 112; Schizophrenia, n = 163) and 126 healthy controls that were recruited across six sites in the B-SNIP consortium. VEGFA variants identified for analysis (rs699947, rs833070, and rs2146323) were quantified via SNP chip array. We assessed symptoms and cognition using standardized clinical and neuropsychological batteries. The dorsolateral prefrontal cortex (DLPFC), medial temporal lobe, and hippocampal volumes were quantified using FreeSurfer. In our sample, VEGFA rs2146323 A- carriers showed reduced odds of being a proband (p = 0.037, OR = 0.65, 95% CI = 0.43-0.98) compared to noncarriers, but not for rs699947 or rs833070. In probands, rs2146323 A- carriers demonstrated fewer hallucinations (p = 0.035, Cohen's d = 0.194), as well as significantly greater DLPFC (p < 0.05, Cohen's d = -0.21) and parahippocampal volumes (p < 0.01, Cohen's d = -0.27). No clinical or neuroimaging associations were identified for rs699947 or rs833070. In general, we found that the three SNPs exhibited several significant negative relationships between psychosis symptoms and brain structure. In the probands and control groups, positive relationships were identified between several cognitive and brain volume measures. The findings suggest VEGFA effects in the DLPFC and hippocampus found in animals may also extend to humans. VEGFA variations may have important implications in identifying dimensional moderators of function that could be targeted through VEGFA-mediated interventions.